5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043954 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Vanessa M Diaz Almanzar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA. Hauptthemen laut MEDLINE: Fluorouracil, MicroRNAs, Pancreatic Stellate Cells, Pancreatitis, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Chronic pancreatitis is characterized by chronic inflammation and fibrosis, processes heightened by activated pancreatic stellate cells (PSCs). Recent publications have demonstrated that miR-15a, which targets YAP1 and BCL-2, is significantly downregulated in patients with chronic pancreatitis compared to healthy controls. We have utilized a miRNA modification strategy to enhance the therapeutic efficacy of miR-15a by replacing uracil with 5-fluorouracil (5-FU). We demonstrated increased levels of YAP1 and BCL-2 (both targets of miR-15a) in pancreatic tissues obtained from Ptf1aCreERTM and Ptf1aCreERTM;LSL-KrasG12D mice after chronic pancreatitis induction as compared to controls. In vitro studies showed that delivery of 5-FU-miR-15a significantly decreased viability, proliferation, and migration of PSCs over six days compared to 5-FU, TGFβ1, control miR, and miR-15a. In addition, treatment of PSCs with 5-FU-miR-15a in the context of TGFβ1 treatment exerted a more substantial effect than TGFβ1 alone or when combined with other miRs. Conditioned medium obtained from PSC cells treated with 5-FU-miR-15a significantly inhibits the invasion of pancreatic cancer cells compared to controls. Importantly, we demonstrated that treatment with 5-FU-miR-15a reduced the levels of YAP1 and BCL-2 observed in PSCs. Our results strongly suggest that ectopic delivery of miR mimetics is a promising therapeutic approach for pancreatic fibrosis and that 5-FU-miR-15a shows specific promise.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA.
- Department of Pathology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA.
ORCID-Profile: Vanessa M Diaz Almanzar, Joseph F LaComb, Agnieszka B Bialkowska
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Almanzar, V. M. D., Shah, K., LaComb, J. F., Mojumdar, A., Patel, H. R., Cheung, J., Tang, M., Ju, J., & Bialkowska, A. B. (2023). 5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043954
Vancouver
Almanzar VMD, Shah K, LaComb JF, Mojumdar A, Patel HR, Cheung J, et al. 5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043954
BibTeX
@article{Almanzar2023,
author = {Almanzar, Vanessa M Diaz and Shah, Kunal and LaComb, Joseph F and Mojumdar, Aisharja and Patel, Hetvi R and Cheung, Jacky and Tang, Meiyi and Ju, Jingfang and Bialkowska, Agnieszka B},
title = {5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043954}
}
EUVIMED